




Searching News Database: sublingual tablet
HSMN NewsFeed - 2 Jul 2020
Orexo Launches Deprexis(R) and Vorvida(R) in the US and Provides Updated Financial Guidance
Orexo Launches Deprexis(R) and Vorvida(R) in the US and Provides Updated Financial Guidance
HSMN NewsFeed - 29 May 2020
AcelRx Pharmaceuticals Announces Revised Merger Agreement with Tetraphase
AcelRx Pharmaceuticals Announces Revised Merger Agreement with Tetraphase
HSMN NewsFeed - 30 Apr 2020
AcelRx Announces DSUVIA(R) Milestone C Approval and Provides Business Update
AcelRx Announces DSUVIA(R) Milestone C Approval and Provides Business Update
HSMN NewsFeed - 19 Jul 2017
AcelRx Pharmaceuticals Appoints Raffi Asadorian as Chief Financial Officer
AcelRx Pharmaceuticals Appoints Raffi Asadorian as Chief Financial Officer
HSMN NewsFeed - 17 Feb 2017
AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer
AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer
HSMN NewsFeed - 6 Oct 2016
U.S. FDA Approves Orexo's Low Dose ZUBSOLV(R) Buprenorphine and Naloxone Sublingual Tablets (CIII)
U.S. FDA Approves Orexo's Low Dose ZUBSOLV(R) Buprenorphine and Naloxone Sublingual Tablets (CIII)
HSMN NewsFeed - 20 Sep 2016
Lannett Announces Approval For Buprenorphine And Naloxone Sublingual Tablets, 2 mg/0.5 mg And 8 mg/2 mg
Lannett Announces Approval For Buprenorphine And Naloxone Sublingual Tablets, 2 mg/0.5 mg And 8 mg/2 mg
HSMN NewsFeed - 19 Jan 2016
Akorn Launches Buprenorphine/Naloxone Sublingual Tablets and Tobramycin Injection
Akorn Launches Buprenorphine/Naloxone Sublingual Tablets and Tobramycin Injection
HSMN NewsFeed - 1 Oct 2015
AcelRx Pharmaceuticals Appoints Gina Ford as Vice President Commercial Strategy
AcelRx Pharmaceuticals Appoints Gina Ford as Vice President Commercial Strategy
HSMN NewsFeed - 21 Aug 2014
Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer
Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer
HSMN NewsFeed - 16 Dec 2013
AcelRx and Grunenthal Announce Collaboration for EU Commercialization of ZALVISO(TM)
AcelRx and Grunenthal Announce Collaboration for EU Commercialization of ZALVISO(TM)
HSMN NewsFeed - 2 Dec 2013
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
HSMN NewsFeed - 20 Aug 2013
Mallinckrodt Pharmaceuticals Signs Distribution Agreement with Amneal Pharmaceuticals LLC
Mallinckrodt Pharmaceuticals Signs Distribution Agreement with Amneal Pharmaceuticals LLC
HSMN NewsFeed - 5 Jul 2013
U.S. FDA Approves Zubsolv(R) for the Maintenance Treatment of Opioid Dependence
U.S. FDA Approves Zubsolv(R) for the Maintenance Treatment of Opioid Dependence
HSMN NewsFeed - 5 Apr 2012
Transcept Pharmaceuticals Announces National Product Launch of Intermezzo(R) by Purdue Pharma L.P.
Transcept Pharmaceuticals Announces National Product Launch of Intermezzo(R) by Purdue Pharma L.P.
HSMN NewsFeed - 14 Jan 2011
Orexo and Invida Jointly Announce Agreement for Abstral(TM) in Asia Pacific
Orexo and Invida Jointly Announce Agreement for Abstral(TM) in Asia Pacific
HSMN NewsFeed - 10 Jan 2011
Orexo: FDA Approval For Abstral (Fentanyl) Sublingual Tablets - US Launch Planned For Q1 2011
Orexo: FDA Approval For Abstral (Fentanyl) Sublingual Tablets - US Launch Planned For Q1 2011
HSMN NewsFeed - 22 Feb 2010
Transcept Pharmaceuticals Provides Update on Intermezzo(R) Regulatory Review
Transcept Pharmaceuticals Provides Update on Intermezzo(R) Regulatory Review
HSMN NewsFeed - 29 Oct 2009
Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
HSMN NewsFeed - 16 Mar 2009
Orexo's Edluar (Sublinox) Receives FDA Approval for the Treatment of Insomnia
Orexo's Edluar (Sublinox) Receives FDA Approval for the Treatment of Insomnia
HSMN NewsFeed - 2 Mar 2009
Orexo's AbstralTM Receives Two Further Large EU Market Approvals in France and Spain
Orexo's AbstralTM Receives Two Further Large EU Market Approvals in France and Spain
HSMN NewsFeed - 20 May 2008
Biodel Inc. Announces Appointment of Alan Krasner, M.D. as Chief Medical Officer
Biodel Inc. Announces Appointment of Alan Krasner, M.D. as Chief Medical Officer
HSMN NewsFeed - 14 Nov 2007
Biodel Inc. Announces Appointment of Gerard Michel as CFO, VP of Corporate Development and Treasurer
Biodel Inc. Announces Appointment of Gerard Michel as CFO, VP of Corporate Development and Treasurer
HSMN NewsFeed - 14 Nov 2007
Study Shows Organon's Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia
Study Shows Organon's Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia
HSMN NewsFeed - 25 Oct 2007
Orexo Signs Distribution Agreement with Hospira in Asia for Pain Product Rapinyl(TM)
Orexo Signs Distribution Agreement with Hospira in Asia for Pain Product Rapinyl(TM)
HSMN NewsFeed - 6 Oct 2006
SUBOXONE(R) (Buprenorphine/Naloxone) Approved In European Union for Treatment of Opioid Dependence
SUBOXONE(R) (Buprenorphine/Naloxone) Approved In European Union for Treatment of Opioid Dependence
Additional items found! 1

Members Archive contains
1 additional stories matching:
sublingual tablet
(Password required)
sublingual tablet
(Password required)